TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 26427866
Drug: Lidocaine with
Normalized name: Lidocaine with Tegaderm
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine with epinephrine (LE; 1:80,000) and Lidocaine with clonidine (LC; 15 mcg/ml)
Study: 10769603
Drug: Phyllanthus amarus
Normalized name: Phyllanthus amarus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phyllanthus amarus (300 mg capsules, 3 capsules thrice daily)
Study: 10769603
Drug: Placebo (antacid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (antacid powder in similar capsule form)
Study: 6846115
Drug: Acebutolol (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acebutolol (both doses)
Study: 15788107
Drug: 375 ml
Normalized name: isopropyl alcohol 0.0375 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 375 ml red wine daily for 2 weeks
Study: 1835850
Drug: Combination chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination chemotherapy with cisplatin
Study: 7039400
Drug: Terbutaline depot
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terbutaline depot tablets 7.5 mg twice a day
Study: 7039400
Drug: Terbutaline tablets
Normalized name: terbutaline Oral Tablet
DrugBank: Terbutaline (DB00871)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Terbutaline tablets 5 mg three times a day
Study: 31727415
Drug: Dienogest 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dienogest 0.5 mg/d
Study: 31727415
Drug: Dienogest 1
Normalized name: Dienogest
DrugBank: Dienogest (DB09123)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dienogest 1 mg/d
Study: 31727415
Drug: Dienogest 2
Normalized name: dienogest 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dienogest 2 mg/d
Study: 31727415
Drug: Ethinylestradiol 0.02
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ethinylestradiol 0.02 mg/drospirenone 3 mg (reference drug)
Study: 27419081
Drug: Ginger powder
Normalized name: Emergen-C Turmeric & Ginger Powder for Solution (Citrus-Ginger)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ginger powder supplementation (1 g/d)
Study: 27419081
Drug: Placebo (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (500 mg starch)
Study: 20726255
Drug: OPV (HDC)
Normalized name: Opvee
DrugBank: Oral Polio Vaccine (DB15864)
Approvals — FDA: no, EMA: no, PMDA: no
Description: OPV (HDC) vaccine
Study: 16171661
Drug: Hypotensive total
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypotensive total intravenous anesthesia (HTIVA) with propofol and remifentanil (n = 20)
Study: 12606177
Drug: Buprenorphine (16
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buprenorphine (16 mg sublingually for 12 months; supervised daily administration for at least 6 months, possible take-home doses thereafter)
Study: 10531156
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate (FP) by pMDI, 1.76 mg (250 microg ex-valve, 220 microg ex-actuator)
Study: 10531156
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate (FP) by pMDI with 750-mL spacer
Study: 1834093
Drug: Enalapril (5‐20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril (5‐20 mg daily)
Study: 7035545
Drug: Sequential Spironolactone
Normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sequential Spironolactone
Study: 7035545
Drug: Combination (spironolactone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination (spironolactone and furosemide)
Study: 25453457
Drug: Aspirin 325
Normalized name: aspirin 325 MG
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin 325 mg plus clopidogrel 75 mg
Study: 25453457
Drug: Aspirin 325
Normalized name: aspirin 325 MG
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin 325 mg plus placebo
Study: 21336429
Drug: Eicosapentaenoic Acid‐enriched
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eicosapentaenoic Acid‐enriched oral nutritional supplement (2 packs per day for 12 weeks) plus dietary counseling
Study: 15920225
Drug: HES 264/0.45
Approvals — FDA: no, EMA: no, PMDA: no
Description: HES 264/0.45 (up to 45 mL/kg)
Study: 15920225
Drug: 5% albumin
Normalized name: Flexbumin 5% Albumin (Human) Solution for Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% albumin (up to 45 mL/kg)
Study: 9669185
Drug: Fluvoxamine 100
Normalized name: fluvoxamine 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluvoxamine 100 mg a day
Study: 2374564
Drug: Active injections
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active injections of suspected allergens (60 total injections)
Study: 2374564
Drug: Control injections
Normalized name: Afeditab CR
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Control injections (180 total injections)
Study: 2374564
Drug: Neutralizing doses
Normalized name: DentiCare Neutral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neutralizing doses given by physicians (both suspected allergen and saline)
Study: 16635
Drug: Dichloralphenazone 1300
Normalized name: Dichloralphenazone
DrugBank: Dichloralphenazone (DB01495)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dichloralphenazone 1300 mg
Study: 28239939
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of sitagliptin 100 mg plus fasiglifam 25 mg
Study: 28239939
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of sitagliptin 100 mg plus fasiglifam 50 mg
Study: 28239939
Drug: Fasiglifam 25
Normalized name: Fasiglifam
DrugBank: Fasiglifam (DB12491)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fasiglifam 25 mg monotherapy
Study: 28239939
Drug: Fasiglifam 50
Normalized name: Fasiglifam
DrugBank: Fasiglifam (DB12491)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fasiglifam 50 mg monotherapy
Study: 17276718
Drug: Insulin glargine
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin glargine administered at dinner (n=589)
Study: 17276718
Drug: Insulin glargine
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin glargine administered at bedtime (n=589)
Study: 17276718
Drug: Insulin glargine
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin glargine at dinner (FAA subgroup)
Study: 17276718
Drug: Insulin glargine
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin glargine at bedtime (FAA subgroup)
Study: 17276718
Drug: Insulin glargine
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin glargine at dinner (RHI subgroup)
Study: 17276718
Drug: Insulin glargine
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin glargine at bedtime (RHI subgroup)
Study: 11317534
Drug: Breast conserving
Normalized name: chicken breast preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Breast conserving treatment (quandrantectomy + radiation)
Study: 9681665
Drug: Topical aspirin/diethyl
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical aspirin/diethyl ether (ADE) mixture (750 mg)
Study: 9681665
Drug: Oral aspirin
Normalized name: aspirin Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral aspirin (500 mg)
Study: 7927958
Drug: Policosanol 5
Normalized name: policosanol 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Policosanol 5 mg once-a-day for 8 weeks
Study: 7927958
Drug: Policosanol 5
Normalized name: policosanol 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Policosanol 5 mg twice-a-day for 8 weeks
Study: 7927958
Drug: Policosanol 10
Normalized name: policosanol 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Policosanol 10 mg twice-a-day for 8 weeks
Study: 2502890
Drug: Antithymocyte globulin
Normalized name: Rabbit antithymocyte globulin
DrugBank: Antithymocyte immunoglobulin (rabbit) (DB00098)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antithymocyte globulin (ATG) therapy, 5 doses every other day, 60-min intravenous infusion
Study: 2502890
Drug: Antithymocyte globulin
Normalized name: Rabbit antithymocyte globulin
DrugBank: Antithymocyte immunoglobulin (rabbit) (DB00098)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antithymocyte globulin (ATG) therapy
Study: 12221048
Drug: Full-dose almonds
Approvals — FDA: no, EMA: no, PMDA: no
Description: Full-dose almonds (73±3 g/d)
Study: 18555827
Drug: Half-dose almonds
Approvals — FDA: no, EMA: no, PMDA: no
Description: Half-dose almonds
Study: 10878510
Drug: Phenoxymethylpenicillin (40‐60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenoxymethylpenicillin (40‐60 mg/kg/day) for 10 days (n = 28)
Study: 10878510
Drug: Amoxicillin‐clavulanic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin‐clavulanic acid (20‐40 mg/kg/day) for 10 days (n = 23)
Study: 7793184
Drug: Midazolam (0.13
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam (0.13 mg.kg‐1)
Study: 7793184
Drug: Thiopental (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thiopental (4 mg.kg‐1)
Study: 7793184
Drug: Midazolam (0.13
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam (0.13 mg.kg‐1) combined with Flumazenil (6 micrograms.kg‐1)
Study: 7004999
Drug: Motilin infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Motilin infusion of 0.2 pmol/kg/min
Study: 6143184
Drug: Relaxation therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Relaxation therapy alone (group A)
Study: 25917895
Drug: Probiotic treatment
Normalized name: Rezyst Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic treatment with Saccharomyces boulardii (n = 15)
Study: 25917895
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment (n = 18)
Study: 16030100
Drug: Twice-weekly weight
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice-weekly weight training (0 to 12 months)
Study: 16030100
Drug: Delayed treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed treatment group (no exercise for 6 months, then training for 6 months)
Study: 10521838
Drug: Direct preparations
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Direct preparations and cultured cells
Study: 2074162
Drug: Naproxen sodium
Normalized name: Naproxen Sodium
DrugBank: Naproxen (DB00788)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Naproxen sodium (Nxs) 550 mg twice each day by mouth
Study: 7018862
Drug: Cimetidine (dosage
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine (dosage not specified)
Study: 7018862
Drug: Antacid (specific
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antacid (specific type not mentioned)
Study: 30606161
Drug: Text messages
Approvals — FDA: no, EMA: no, PMDA: no
Description: Text messages about the availability of oral HIV self-test kits sent three times to the intervention group.
Study: 26355952
Drug: Hydrolyzed water‐soluble
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrolyzed water‐soluble egg membrane (WSEM), 450 mg daily
Study: 20027498
Drug: Recombinant Hepatitis
Normalized name: Recombinant hepatitis B human immunoglobulin
DrugBank: Lenvervimab (DB17814)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant Hepatitis B vaccine (VrHB‐IB)
Study: 20027498
Drug: Recombinant Hepatitis
Normalized name: Recombinant hepatitis B human immunoglobulin
DrugBank: Lenvervimab (DB17814)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant Hepatitis B vaccine (VrHB‐IB) with increased antigen concentration to 25 microg
Study: 20027498
Drug: Control (reference
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (reference vaccine)
Study: 12782208
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg aspartame
Study: 12782208
Drug: 176 mg
Normalized name: salicylic acid 176 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 176 mg aspartic acid + 224 mg phenylalanine
Study: 12782208
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg corn flour (control)
Study: 7676242
Drug: Amoxicillin plus
Normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amoxicillin plus gentamicin
Study: 9315991
Drug: 15 mg
Normalized name: papain 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg quazepam
Study: 22030088
Drug: 200-mg twice
Normalized name: BCG, live, Tice strain 50 MG/ML [Tice BCG]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200-mg twice daily celecoxib
Study: 22030088
Drug: 400-mg twice
Normalized name: BCG, live, Tice strain 50 MG/ML [Tice BCG]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400-mg twice daily celecoxib
Study: 22030088
Drug: Withdrawal of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Withdrawal of 200-mg twice daily celecoxib
Study: 22030088
Drug: Withdrawal of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Withdrawal of 400-mg twice daily celecoxib
Study: 22030088
Drug: Concurrent use
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent use of low-dose aspirin
Study: 17884846
Drug: Transport with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transport with tirofiban (10 microg/kg bolus i.v. + i.v. infusion 0.1 microg/kg/min) for primary PCI
Study: 12744577
Drug: Real ECT
Normalized name: REAL FOODS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Real ECT treatment
Study: 12744577
Drug: Simulated ECT
Normalized name: bisacodyl
DrugBank: Bisacodyl (DB09020)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Simulated ECT treatment (Control)
Study: 30796112
Drug: Pump Suspension
Normalized name: INTESTINAL PUMP SUSPENSION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pump Suspension (PS) at exercise onset
Study: 28434463
Drug: Prenatal yoga
Normalized name: Ardisia crenata root extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prenatal yoga (20-week intervention with two weekly 70-min yoga sessions led by a certified midwife)
Study: 24113059
Drug: Topical formalin
Normalized name: formalin
DrugBank: Formaldehyde (DB03843)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical formalin
Study: 21982170
Drug: Halothane anesthesia
Normalized name: Halothane
DrugBank: Halothane (DB01159)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Halothane anesthesia with oral midazolam premedication (0.5mg/kg 20‐30 minutes before induction)
Study: 21982170
Drug: Sevoflurane anesthesia
Normalized name: Sevoflurane
DrugBank: Sevoflurane (DB01236)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sevoflurane anesthesia with oral midazolam premedication
Study: 17678651
Drug: Vaginal estradiol
Normalized name: estradiol Vaginal Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaginal estradiol supplementation (E(2) 2 mg twice a day starting on the day of ET)
Study: 17678651
Drug: Vaginal estradiol
Normalized name: estradiol Vaginal Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaginal estradiol supplementation (E(2) 2 mg twice a day starting on the day of ET) in long GnRH agonist suppression protocol
Study: 17678651
Drug: No E(2)
Approvals — FDA: no, EMA: no, PMDA: no
Description: No E(2) supplementation (control group) in long GnRH agonist suppression protocol
Study: 17678651
Drug: Vaginal estradiol
Normalized name: estradiol Vaginal Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaginal estradiol supplementation (E(2) 2 mg twice a day starting on the day of ET) in GnRH antagonist or microdose GnRH agonist protocols
Study: 17678651
Drug: No E(2)
Approvals — FDA: no, EMA: no, PMDA: no
Description: No E(2) supplementation (control group) in GnRH antagonist or microdose GnRH agonist protocols
Study: 16533095
Drug: 8-week, one-on-one
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8-week, one-on-one book-sharing intervention with twice-weekly 15-min sessions
Study: 14700441
Drug: 1% topical
Normalized name: SSD 1% Topical Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% topical pimecrolimus cream
Study: 27389963
Drug: Basic periodontal
Normalized name: Basic Fuchsin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Basic periodontal therapy + 0.12% chlorhexidine
Study: 27389963
Drug: Basic periodontal
Normalized name: Basic Fuchsin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Basic periodontal therapy + placebo
Study: 23040413
Drug: L-arginine-enriched biscuits
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-arginine-enriched biscuits
Study: 23040413
Drug: Powdered L-arginine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Powdered L-arginine
Study: 21569473
Drug: 4 l/min
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 l/min of oxygen from a simple face mask
Study: 21569473
Drug: 4 l/min
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 l/min air from a face mask
Study: 16957557
Drug: Rofecoxib 50
Normalized name: rofecoxib 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rofecoxib 50 mg once/day
Study: 16957557
Drug: Celecoxib 400
Normalized name: celecoxib 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Celecoxib 400 mg once/day
Study: 11110735
Drug: Candesartan 16
Normalized name: candesartan 16 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Candesartan 16 mg once daily
Study: 11110735
Drug: Combination treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination treatment (Candesartan + Lisinopril)
Study: 9066184
Drug: Oxatomide (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxatomide (1 to 2 mg/kg body weight, twice daily)
Study: 3089465
Drug: Adenosine (maximum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adenosine (maximum tolerable dose ranging from 10.6 to 37.1 mg)
Study: 12357162
Drug: Aminophylline 5
Normalized name: aminophylline 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aminophylline 5 mg/kg
Study: 3089465
Drug: Dipyridamole 10
Normalized name: dipyridamole 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dipyridamole 10 mg
Study: 22870960
Drug: Low-level laser
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-level laser therapy (LLLT) with 5.1J (60J/cm²) energy density, applied at three different points intraorally immediately and at 48 and 72 hours post-surgery
Study: 20046173
Drug: Ketamine (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine (1.5 mg/kg) and Diazepam (0.1 mg/kg)
Study: 20046173
Drug: Midazolam (0.05
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam (0.05 mg/kg) and Fentanyl (1 microg/kg)
Study: 16322468
Drug: Total therapy
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total therapy 1 (TT1)
Study: 18371114
Drug: Total therapy
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total therapy 2 (TT2) without THAL
Study: 18371114
Drug: Total therapy
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total therapy 2 (TT2)
Study: 18371114
Drug: Total therapy
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total therapy 2 (TT2) without cytogenetic abnormalities (CA)
Study: 18371114
Drug: Total therapy
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total therapy 2 (TT2) with cytogenetic abnormalities (CA)
Study: 8227859
Drug: Terfenadine (antihistamine)
Normalized name: terfenadine Oral Tablet [Antihistamine Forte]
DrugBank: Terfenadine (DB00342)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Terfenadine (antihistamine)
Study: 30370830
Drug: Daily oral
Normalized name: GEMTESA 75 MG Once-Daily Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily oral and vaginal tenofovir formulations for HIV prevention
Study: 18327092
Drug: 'in‐treatment' segmental
Approvals — FDA: no, EMA: no, PMDA: no
Description: 'in‐treatment' segmental wall motion abnormalities
Study: 15796632
Drug: Delayed treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed treatment (DTC)
Study: 1908604
Drug: Almitrine 100
Normalized name: almitrine
DrugBank: Almitrine (DB01430)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Almitrine 100 mg twice a day reducing to 50 mg twice a day over 48 hours
Study: 6150839
Drug: Bisoprolol 5
Normalized name: bisoprolol 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bisoprolol 5 mg and 10 mg doses per 24 hours
Study: 26415520
Drug: Self-efficacy enhancement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-efficacy enhancement program (three individualized in-hospital education sessions and three weekly sessions of telephone counseling)
Study: 26415520
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (supervised exercise and activities of daily living performance regimen, education)
Study: 16137275
Drug: Daily multidisciplinary
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily multidisciplinary geriatric intervention (n=155)
Study: 12177585
Drug: Haloperidol (3-15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haloperidol (3-15 mg/day)
Study: 20008235
Drug: Non-ASCT strategies
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-ASCT strategies (salvage radiotherapy or non-ASCT chemotherapy)
Study: 17464688
Drug: Computerized cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Computerized cognitive behavioural therapy (CCBT)
Study: 15675207
Drug: 4 ml
Normalized name: ethanol 1.4 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 ml 1% lignocaine pre‐treatment followed by propofol and 2 ml saline
Study: 15675207
Drug: 4 ml
Normalized name: ethanol 1.4 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 ml saline followed by propofol and 2 ml 2% lignocaine
Study: 11704028
Drug: High-dose vitamin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose vitamin and mineral supplements
Study: 2853459
Drug: Unfractionated heparin
Normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Unfractionated heparin (5,000 units every 8 hours)
Study: 30516625
Drug: Tranexamic Acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tranexamic Acid (TXA) 50 mg/kg loading dose and 10 mg/kg/h infusion
Study: 25609939
Drug: Concurrent medications
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent medications considered strong or moderate inhibitors of CYP2D6
Study: 25609939
Drug: Concurrent medications
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent medications considered strong or moderate inhibitors of CYP3A4/5